5-FU and the dietary flavonoid carvacrol: a synergistic combination that induces apoptosis in MCF-7 breast cancer cells

Azimi, Saleh; Lashgarian, Hamed Esmaeil; Ghorbanzadeh, Vajihe; Moradipour, Ayat; Pirzeh, Lale; Dariushnejad, Hassan

doi:10.1007/s12032-022-01863-0

Cited by 6 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The IC50 values of drug combinations exhibited more pronounced dose-dependent growth inhibition of MCF-7 and HeLa cells as compared to alone drugs. These results coincide with the findings of a previous study . The SI of all alone and drug combinations exhibited cytotoxicity toward cancerous cells with anticancer potential.…”

Section: Discussionsupporting

confidence: 92%

“…These results coincide with the findings of a previous study. 49 The SI of all alone and drug combinations exhibited cytotoxicity toward cancerous cells with anticancer potential. Dose effect curves for every single drugs and their binary combination were plotted, and it was revealed that carvacrol nanoparticles in combination with doxorubicin exhibited significant growth inhibition of MCF-7 and HeLa cells as compared to other combinations.…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Carvacrol-Fabricated Chitosan Nanoparticle Synergistic Potential with Topoisomerase Inhibitors on Breast and Cervical Cancer Cells

Akhlaq,

Ashraf,

Omer

et al. 2023

ACS Omega

View full text Add to dashboard Cite

Breast and cervical cancers are the most common heterogeneous malignancies in women. Chemotherapy with conventional drug delivery systems having several limitations along with development of multidrug resistance compelled us to seek out targeted therapeutics. Nanoparticles are suitable substitutes to circumvent multidrug resistance for the targeted treatment of cancer. The current study was aimed to investigate the anticancer effect of carvacrolloaded chitosan nanoparticles with topoisomerase inhibitors. The average size of carvacrol-loaded chitosan nanoparticles was found to be 80 nm with 24.7 mV ζpotential, and maximum absorbance was observed at 275 nm. Among all drug combinations, the carvacrol nanoparticles with the doxorubicin combination group exerted greater dose-dependent growth inhibition of both MCF-7 and HeLa cells as compared to single carvacrol nanoparticles and doxorubicin. Combination index values of carvacrol nanoparticles and the doxorubicin combination group showed a strong synergistic effect as they were found to be between 0.2 and 0.4, 0.31 for MCF-7 and 0.34 for HeLa cells. The carvacrol nanoparticles in combination with doxorubicin on MCF-7 cells reduced the dose 16.32-fold for carvacrol nanoparticles and 4.09-fold for doxorubicin at 6.23 μg/mL IC 50 , while on HeLa cells, this combination reduced the dose 13.18-fold for carvacrol nanoparticles and 3.83-fold for doxorubicin at 9.33 μg/mL IC 50 . As the dose reduction values were greater than 1, they indicated favorable dose reduction. It was concluded that the combination of carvacrol-loaded chitosan nanoparticles with topoisomerase inhibitors may represent an innovative and promising strategy to improve the efficacy, resistance, and targeted delivery of chemotherapeutics in cancer.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 98%

Carvacrol-Fabricated Chitosan Nanoparticle Synergistic Potential with Topoisomerase Inhibitors on Breast and Cervical Cancer Cells

Akhlaq,

Ashraf,

Omer

et al. 2023

ACS Omega

View full text Add to dashboard Cite

show abstract

“…However, their efficacy in both combination therapy and monotherapy is compromised by some limitations, e.g., poor bioavailability, etc. [43][44][45]. Hence, better strategies to improve their therapeutic effect are a pressing need.…”

mentioning

confidence: 99%

Carvacrol and Thymol Hybrids: Potential Anticancer and Antibacterial Therapeutics

Peter,

Sotondoshe,

Aderibigbe

2024

Molecules

View full text Add to dashboard Cite

Cancer is ranked among lethal diseases globally, and the increasing number of cancer cases and deaths results from limited access to effective therapeutics. The use of plant-based medicine has been gaining interest from several researchers. Carvacrol and its isomeric compound, thymol, are plant-based extracts that possess several biological activities, such as antimalarial, anticancer, antifungal, and antibacterial. However, their efficacy is compromised by their poor bioavailability. Thus, medicinal scientists have explored the synthesis of hybrid compounds containing their pharmacophores to enhance their therapeutic efficacy and improve their bioavailability. Hence, this review is a comprehensive report on hybrid compounds containing carvacrol and its isomer, thymol, with potent anticancer and antibacterial agents reported between 2020 and 2024. Furthermore, their structural activity relationship (SAR) and recommended future strategies to further enhance their therapeutic effects will be discussed.

show abstract

Carvacrol protects rats against bleomycin-induced lung oxidative stress, inflammation, and fibrosis

Pashmforosh,

Rajabi Vardanjani,

Khorsandi

et al. 2024

Naunyn-Schmiedeberg's Arch Pharmacol

View full text Add to dashboard Cite

5-FU and the dietary flavonoid carvacrol: a synergistic combination that induces apoptosis in MCF-7 breast cancer cells

Cited by 6 publications

References 24 publications

Carvacrol-Fabricated Chitosan Nanoparticle Synergistic Potential with Topoisomerase Inhibitors on Breast and Cervical Cancer Cells

Carvacrol-Fabricated Chitosan Nanoparticle Synergistic Potential with Topoisomerase Inhibitors on Breast and Cervical Cancer Cells

Carvacrol and Thymol Hybrids: Potential Anticancer and Antibacterial Therapeutics

Carvacrol protects rats against bleomycin-induced lung oxidative stress, inflammation, and fibrosis

Contact Info

Product

Resources

About